+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biomarkers Market - Global Forecast 2026-2032- Product Image
Cancer Biomarkers Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Biomarkers Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4858011
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Biomarkers Market is projected to reach USD 38.13 Billion in 2026. It is expected to continue growing at a CAGR of 11.09%, reaching USD 72.41 Billion by 2032.

Cancer biomarkers are measurable biological signals that help detect malignancy, classify tumors, predict treatment response, monitor minimal residual disease, and identify relapse earlier than conventional methods. Demand is anchored in the global cancer burden: IARC’s GLOBOCAN 2022 estimated about 20 million new cancer cases and 9.7 million cancer deaths worldwide, underscoring the need for earlier diagnosis, precision oncology, and longitudinal disease monitoring.

The field is moving from single-analyte testing toward integrated genomic, proteomic, epigenetic, metabolomic, and immune-profile biomarkers. Clinically established examples such as EGFR, ALK, HER2, BRCA1/2, PD-L1, MSI-H/dMMR, NTRK, and circulating tumor DNA are shaping companion diagnostics, targeted therapies, immuno-oncology decisions, and value-based cancer care across solid tumors and hematologic malignancies.

Transformative Shifts in the Cancer Biomarkers Landscape

The cancer biomarkers landscape is being reshaped by next-generation sequencing, liquid biopsy, multiplex immunohistochemistry, digital pathology, and decentralized sample collection. FDA-cleared and FDA-approved comprehensive genomic profiling tests have accelerated clinical adoption by linking biomarker results to targeted therapies, tumor-agnostic indications, hereditary cancer risk assessment, and immuno-oncology decisions.

A second shift is the expansion of biomarkers beyond late-stage treatment selection. Screening, early detection, therapy monitoring, and recurrence surveillance are gaining investment as clinicians seek faster, less invasive, and more longitudinal insight into tumor biology. This shift is also increasing demand for standardized pre-analytical workflows, harmonized reporting, external quality assessment, and evidence demonstrating clinical utility in real-world oncology practice.

Cumulative Impact of Artificial Intelligence on Cancer Biomarkers

Artificial intelligence is amplifying cancer biomarker discovery by analyzing pathology images, radiology data, multi-omics datasets, and real-world clinical records at scale. Public resources such as The Cancer Genome Atlas, which profiled more than 20,000 primary cancer and matched normal samples across 33 cancer types, provide a foundation for algorithmic biomarker research and molecular subtype classification.

AI is also improving workflow efficiency in laboratories by supporting variant interpretation, image quantification, quality control, patient stratification, and trial matching. The strongest near-term opportunity is not replacing expert judgment but combining machine learning with validated assays, transparent evidence, bias monitoring, data governance, and regulated clinical decision support that can be audited in routine cancer care.

Key Regional Insights Across Cancer Biomarker Adoption

North America remains a leading region for cancer biomarkers due to high oncology R&D intensity, broad access to advanced diagnostics, active FDA pathways for companion diagnostics, and extensive clinical trial networks. The United States and Canada benefit from established molecular pathology capabilities, national cancer research infrastructure, and growing use of liquid biopsy and comprehensive genomic profiling in oncology care. Europe benefits from strong academic oncology centers, EMA-aligned precision medicine frameworks, the European Health Data Space agenda, and cross-border research initiatives, although reimbursement, laboratory accreditation, and data-governance variation still affect adoption across countries.

Asia-Pacific is the fastest-evolving opportunity as China, Japan, India, South Korea, and Australia expand genomic medicine, oncology screening, national cancer strategies, and local diagnostic manufacturing capacity. Japan and South Korea demonstrate strong regulated adoption of molecular oncology, while China and India are increasing sequencing capacity and cancer diagnostics access for large patient populations. Latin America is improving access through private oncology networks, reference laboratories, and national cancer programs in countries such as Brazil and Mexico, while affordability and uneven specialist access remain constraints. The Middle East is investing in genomic health strategies, cancer centers, and specialty care infrastructure, particularly across Gulf health systems. Africa is gradually building pathology, biobanking, molecular testing, and workforce capacity to address late-stage diagnosis and support equitable cancer biomarker implementation.

Key Group Insights for Cancer Biomarker Growth

Among regional groups, the G7 anchors high-value cancer biomarker innovation through mature regulatory agencies, research funding, advanced oncology reimbursement systems, and deep clinical trial infrastructure. The European Union supports harmonization through the In Vitro Diagnostic Regulation, cancer mission funding, cross-country data initiatives, and quality standards that create demand for validated assays and evidence-based clinical implementation. NATO countries, many of which overlap with advanced oncology economies, increasingly view resilient diagnostic supply chains, laboratory readiness, and health data security as part of broader medical preparedness.

BRICS countries represent scale, epidemiologic diversity, and cost-sensitive innovation, particularly as China and India expand sequencing capacity and Brazil, Russia, and South Africa seek broader oncology diagnostics access under differing health system constraints. ASEAN is advancing cancer diagnostics unevenly across member states, but rising private healthcare investment, medical tourism, and regional reference laboratory models are supporting biomarker testing in urban oncology centers. GCC countries are prioritizing genomics, specialty cancer care, and national precision medicine programs, creating opportunities for molecular testing, companion diagnostics, and AI-enabled oncology workflows within rapidly modernizing health systems.

Key Country Insights in Cancer Biomarkers

The United States leads in companion diagnostics, liquid biopsy adoption, oncology trials, clinical guideline integration, and payer debate over clinical utility. Canada supports precision oncology through provincial genomic testing programs and cancer agencies, while Mexico and Brazil are expanding access through public and private oncology networks but continue to face affordability, referral, and laboratory-capacity constraints. The United Kingdom leverages national health system genomics initiatives and centralized testing pathways, Germany and France maintain strong molecular oncology networks and reimbursement mechanisms, and Italy and Spain are scaling cancer biomarker testing through regional healthcare systems with growing emphasis on standardization and equitable access.

Russia has scientific capability and oncology expertise but faces access, reimbursement, and supply-chain constraints affecting advanced molecular diagnostics. China is rapidly building domestic biomarker platforms, sequencing capacity, and precision oncology programs, while India is growing high-volume molecular diagnostics supported by expanding oncology hospitals and cost-conscious test models. Japan leads in regulated precision medicine adoption, including national approaches to genomic profiling and companion diagnostics. Australia benefits from national genomics programs, strong clinical research networks, and guideline-supported cancer testing, while South Korea combines advanced digital health infrastructure, high screening participation for several cancers, and strong translational cancer research to support biomarker-enabled oncology care.

Actionable Recommendations for Cancer Biomarker Leaders

Industry leaders should prioritize analytically validated assays, clinically meaningful endpoints, and evidence packages that address regulator, oncologist, laboratory, pathologist, and payer requirements. Partnerships among diagnostic developers, therapy developers, hospitals, reference laboratories, and academic cancer centers are essential for generating real-world evidence, improving trial enrollment, and expanding patient access to guideline-recommended biomarker testing.

Organizations should also invest in interoperable data infrastructure, AI governance, biospecimen quality controls, external quality assessment, cybersecurity, and scalable reimbursement strategies. The most defensible positions will combine biomarker science, operational reliability, companion diagnostic expertise, regulatory readiness, and equitable access models across mature and emerging oncology markets.

Research Methodology

Research methodology is built from verified secondary research and evidence synthesis across public health, regulatory, scientific, and industry sources. Core references include WHO and IARC cancer statistics, FDA and EMA diagnostic and therapy guidance, NCI resources, peer-reviewed oncology literature, clinical trial registries, professional guideline publications, and publicly available regulatory documentation.

The methodology emphasizes triangulation across disease burden, regulatory approvals, biomarker utility, technology adoption, reimbursement signals, clinical guideline inclusion, laboratory capacity, and regional healthcare readiness. Insights exclude unsupported market claims and prioritize data-backed trends relevant to cancer biomarker strategy, commercialization, clinical implementation, and precision oncology adoption.

Conclusion

Cancer biomarkers are becoming central to precision oncology as healthcare systems shift from generalized cancer treatment toward molecularly guided prevention, diagnosis, therapy selection, and monitoring. The combination of validated assays, liquid biopsy, AI-enabled analytics, digital pathology, multi-omics profiling, and real-world evidence is expanding the clinical value of biomarker-driven cancer care.

Sustainable advancement will depend on clinical utility, reimbursement clarity, regulatory quality, laboratory standardization, data governance, and equitable access. Organizations that align scientific innovation with practical oncology workflows, evidence generation, and patient-centered implementation will be best positioned to lead the next phase of cancer biomarker adoption.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Biomarkers Market, by Biomarker Type
7.1. Introduction
7.2. Cellular Biomarker
7.3. Genetic Biomarker
7.3.1. DNA Biomarker
7.3.2. Epigenetic Biomarker
7.3.3. RNA Biomarker
7.3.3.1. Long Non-Coding RNA
7.3.3.2. Messenger RNA
7.3.3.3. MicroRNA
7.4. Metabolic Biomarker
7.5. Protein Biomarker
8. Cancer Biomarkers Market, by Technology
8.1. Introduction
8.2. Enzyme Linked Immunosorbent Assay
8.3. Flow Cytometry
8.4. Mass Spectrometry
8.5. Next Generation Sequencing
8.6. Polymerase Chain Reaction
9. Cancer Biomarkers Market, by Cancer Type
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
9.5. Ovarian Cancer
9.6. Prostate Cancer
10. Cancer Biomarkers Market, by Test Type
10.1. Introduction
10.2. Liquid Biopsy
10.3. Tissue Biopsy
11. Cancer Biomarkers Market, by Application
11.1. Introduction
11.2. Companion Diagnostics
11.3. Diagnostics
11.4. Monitoring
11.5. Predictive Testing
11.6. Prognostics
12. Cancer Biomarkers Market, by End User
12.1. Introduction
12.2. Academic Research Institutes
12.3. Biotechnology Companies
12.4. Contract Research Organizations
12.5. Diagnostic Laboratories
12.6. Hospitals
12.7. Pharmaceutical Companies
13. Cancer Biomarkers Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Cancer Biomarkers Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Cancer Biomarkers Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Agilent Technologies, Inc.
17.3. Amoy Diagnostics Co., Ltd.
17.4. Becton, Dickinson and Company
17.5. BGI Genomics Co., Ltd.
17.6. Bio-Rad Laboratories, Inc.
17.7. bioMérieux SA
17.8. Burning Rock Biotech Limited
17.9. Caris Life Sciences, Inc.
17.10. Danaher Corporation
17.11. Exact Sciences Corporation
17.12. F. Hoffmann-La Roche Ltd
17.13. Foundation Medicine, Inc.
17.14. GE HealthCare Technologies Inc.
17.15. Genomic Health, Inc.
17.16. Guardant Health, Inc.
17.17. Hologic, Inc.
17.18. HTG Molecular Diagnostics, Inc.
17.19. Illumina, Inc.
17.20. Invitae Corporation
17.21. Luminex Corporation
17.22. Menarini Silicon Biosystems S.p.A.
17.23. Myriad Genetics, Inc.
17.24. NanoString Technologies, Inc.
17.25. Natera, Inc.
17.26. NeoGenomics Laboratories, Inc.
17.27. Opko Health, Inc.
17.28. PerkinElmer, Inc.
17.29. QIAGEN N.V.
17.30. Quest Diagnostics Incorporated
17.31. Ribomed Biotechnologies, Inc.
17.32. Siemens Healthineers AG
17.33. SOPHiA GENETICS SA
17.34. Sysmex Corporation
17.35. Thermo Fisher Scientific Inc.
17.36. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL CANCER BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER BIOMARKERS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DNA BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL DNA BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL DNA BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RNA BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RNA BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RNA BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MESSENGER RNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MESSENGER RNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MESSENGER RNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. EUROPE CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. EUROPE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 138. EUROPE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 139. EUROPE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 140. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 141. EUROPE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 142. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 144. EUROPE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. AFRICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 156. AFRICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 157. AFRICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 158. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 159. AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 161. AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 162. AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. ASEAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 166. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 167. ASEAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 168. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. ASEAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 170. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 171. ASEAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. ASEAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. GCC CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. GCC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 175. GCC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 176. GCC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 177. GCC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 178. GCC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 179. GCC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 180. GCC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 181. GCC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. BRICS CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. BRICS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 193. BRICS CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 194. BRICS CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 195. BRICS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 196. BRICS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 197. BRICS CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 198. BRICS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 199. BRICS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. G7 CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. G7 CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 202. G7 CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 203. G7 CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 204. G7 CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 205. G7 CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 206. G7 CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 207. G7 CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. G7 CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. NATO CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. NATO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 211. NATO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 212. NATO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 213. NATO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 214. NATO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 215. NATO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 216. NATO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. NATO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. CANADA CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 229. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 230. CANADA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 231. CANADA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 232. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 233. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 234. CANADA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 235. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 236. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. MEXICO CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 239. MEXICO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 240. MEXICO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 241. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 242. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 243. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 244. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 245. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 249. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 250. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 251. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 252. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 253. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 254. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. GERMANY CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 267. GERMANY CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 268. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 269. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 270. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 271. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 272. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. FRANCE CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 275. FRANCE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 276. FRANCE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 277. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 278. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 279. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 280. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 281. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. ITALY CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 293. ITALY CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 294. ITALY CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 295. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 296. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 297. ITALY CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 298. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 299. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. SPAIN CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 302. SPAIN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 303. SPAIN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 304. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 305. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 306. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 307. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 308. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. CHINA CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 311. CHINA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 312. CHINA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 313. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 314. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 315. CHINA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 316. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 317. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. INDIA CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 320. INDIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 321. INDIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 322. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 323. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 324. INDIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 325. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 326. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. JAPAN CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 329. JAPAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 330. JAPAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 331. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 332. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 333. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 334. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 335. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 345. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 347. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2017-2032 (USD MILLION)
TABLE 348. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2017-2032 (USD MILLION)
TABLE 349. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 352. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. GLOBAL CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 355. GLOBAL CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Burning Rock Biotech Limited
  • Caris Life Sciences, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare Technologies Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Menarini Silicon Biosystems S.p.A.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Opko Health, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Ribomed Biotechnologies, Inc.
  • Siemens Healthineers AG
  • SOPHiA GENETICS SA
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.13 Billion
Forecasted Market Value ( USD ) by 2032 $ 72.41 Billion
Compound Annual Growth Rate11.0%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Cancer Biomarkers Market by Profiling Technology, Cancer, Product, Application, End User, And Region - Global Forecast to 2032 - Product Image

Cancer Biomarkers Market by Profiling Technology, Cancer, Product, Application, End User, And Region - Global Forecast to 2032

  • Report
  • 468 Pages
  • Global
From
Cancer Biomarkers - Global Strategic Business Report - Product Image

Cancer Biomarkers - Global Strategic Business Report

  • Report
  • 474 Pages
  • Global
From
Cancer Biomarkers Market - Types, Applications and Technologies - Product Image

Cancer Biomarkers Market - Types, Applications and Technologies

  • Report
  • 326 Pages
  • Global
From
Cancer Biomarker Market Report 2026 - Product Image

Cancer Biomarker Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2026-2034 - Product Image

Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2026-2034

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.